MNOV
No price yet
Announcements
Nothing here yet
Daily updates
- MediciNova reported Phase 2 proof-of-concept findings for MN-001 in non-alcoholic fatty liver disease and hypertriglyceridemia despite missing primary endpoints. The study showed statistically significant increases in HDL-C and HDL-P, initial favorable triglyceride trends, and good tolerability.Oct 12, 2026
- MediciNova is evaluating ibudilast (MN-166) in the COMBAT-ALS Phase 2/3 trial for amyotrophic lateral sclerosis, with topline data expected in late 2026. The study is assessing safety and clinical efficacy following completion of enrollment in September 2025, making the readout a key late-stage catalyst for the ALS program.Oct 4, 2026
- MediciNova reported Phase 2 topline results for MN-001 in NAFLD and hypertriglyceridemia with type 2 diabetes, showing an early significant triglyceride reduction at Week 4 and significant Week 24 increases in HDL-C and HDL-P.Sep 28, 2026
- Roth MKM initiated coverage of MediciNova with a Buy rating and a $6 price targetSep 17, 2026
- MediciNova's Phase 2 MN-001 data were expected in Q3 2026 for metabolic liver diseaseSep 14, 2026
FDA designations
Nothing here yet
News
- MediciNova reports topline results from the MN-001-NATG-202 clinical trial of MN-001 (tipelukast)Sep 28, 2026
- MediciNova completes the last patient, last visit milestone in the double-blind portion of the Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast)Sep 24, 2026
- MediciNova reached a patient enrollment milestone in the expanded-access SEANOBI study of MN-166 for ALSJul 15, 2026
- MediciNova received a patent allowance for MN-166 combined with anti-PD-1 therapy in glioblastomaJun 8, 2026
- MediciNova enrolled 100 ALS patients in SEANOBI expanded-access study of MN-166Jan 30, 2026